Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04685135 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
A Phase 3 study of Metastatic Non Small Cell Lung Cancer and Advanced Non-Small-Cell Lung Cancer, sponsored by Mirati Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 453
- Enrollment target
- 20
- Study locations
NCT04685135 is a Phase 3 study of Metastatic Non Small Cell Lung Cancer and Advanced Non-Small-Cell Lung Cancer that is active but no longer recruiting, run by Mirati Therapeutics. The registered enrollment target is 453 participants, above the 379-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (20% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT04685135, a Phase 3 study of Metastatic Non Small Cell Lung Cancer and Advanced Non-Small-Cell Lung Cancer, is active but no longer recruiting, sponsored by Mirati Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 453 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG MRTX849
Study Locations (20)
California
- Local Institution - 012-898 - Cerritos
- City of Hope - Duarte (Main Campus) - Duarte
- Local Institution - 012-898 D - Glendale
- Local Institution - 012-910-A - Huntington Beach
- Local Institution - 012-910-C - Irvine
- City Of Hope - Long Beach
- Local Institution - 012-910-F - Long Beach
- Local Institution - 012-910-D - Newport Beach
- Local Institution - 012-898 C - Santa Ana
- Providence Medical Group - Santa Rosa - Santa Rosa
- Local Institution - 012-910-E - Torrance
Florida
- Local Institution - 012-562-B - Fleming Island
- Holy Cross Health Fort Lauderdale - Holy Cross Hospital - Fort Lauderdale
- 21st Century Oncology of Jacksonville - North Lee Street - Jacksonville
- Local Institution - 012-562-D - Jacksonville
- Local Institution - 012-562-E - Jacksonville
Colorado
- Local Institution - 012-951-B - Denver
- SCL Health - Saint Joseph Hospital Cancer Center - Lafayette
- Local Institution - 012-872 - Lone Tree
- Local Institution - 012-951-A - Wheat Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 453 participants |
| Start Date | 2021-02-23 |
| Est. Completion | 2026-07-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04685135
The ClinicalTrials.gov registry entry for NCT04685135 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 453 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 379-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (20% higher). The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.
NCT04685135 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT04685135 about?
NCT04685135 is a clinical study titled "Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation". This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.
What is the current status of trial NCT04685135?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 453 participants. The study started on 2021-02-23. Estimated completion is 2026-07-02.
What conditions does trial NCT04685135 study?
This clinical trial studies the following conditions: Metastatic Non Small Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer.
What interventions are being tested in trial NCT04685135?
The interventions under investigation include: Docetaxel (DRUG), MRTX849 (DRUG).
Who is sponsoring clinical trial NCT04685135?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04685135 being conducted?
This trial has 20 study locations across California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Non Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RECRUITING · Phase 3
-
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Metastatic Non Small Cell Lung Cancer
All registered trials for this condition
Advanced Non-Small-Cell Lung Cancer
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.